The hepatitis C treatment Holkira Pak was approved for use in Canada in March 2015 and then was later approved for BC PharmaCare coverage in July 2015. Although Holkira Pak is still approved for use in Canada and has an amazingly high cure rate, as of March 23, 2017, BC PharmaCare has decided not to approve new requests for coverage.
For patients whose coverage was approved before March 23, 2017, BC PharmaCare will continue coverage until their current Special Authority expires. For more information about this change, please contact your doctor, nurse, or call the AbbVie Care program at: 1-844-471-2273.
From all of the BC residents who were able to access Holkira Pak and, therefore, may have been cured of the hepatitis C virus, we would like to thank all of the people who work within the hepatitis C approval pipeline who made their recovery possible.
Treatment Description: Holkira Pak is a treatment for patients with chronic genotype 1 hep C, including those with cirrhosis. It is an all-pill, short-course, interferon-free treatment that can be taken with or without ribavirin.
- Ombitasvir / Paritaprevir / Ritonavir +/-
Daily Dose: 4 pills +/- ribavirin pills
Sustained Viral Response (SVR)/”Cure Rate”: 95 – 100% with ribavirin
Usage Warning: Holkira Pak should not be taken with/by the following:
- Those with moderate to severe liver impairment (Child-Pughs B and C);
- Ethinyl estradiol-containing medicines (such as some birth control products);
- Drugs that are sensitive cytochrome P450 (CYP) 3A substrates and for which elevated plasma concentrations;
- Strong CYP2C8 inhibitors and inducers;
- Moderate or strong inducers of CYP3A;
- Recreational drugs.
Length of Treatment:
|Genotype||Previously Treated||Cirrhosis||Treatment||# of Weeks|
|1a||Yes or No||No||2 pills once daily + 1 pill twice daily + 1 pill twice daily of RBV*||12|
|1b||Yes or No||No||2 pills once daily + 1 pill twice daily||12|
|1a/1b||No||Yes||2 pills once daily + 1 pill twice daily + 1 pill twice daily of RBV||12|
|1a||Yes||Yes||2 pills once daily + 1 pill twice daily + 1 pill twice daily of RBV||24**|
|*RBV stands for ribavirin. Holkira Pak with ribavirin is recommended for patients with an unknown genotype 1 subtype or with mixed genotype.
**24 weeks of Holkira Pak + ribavirin is recommended for patients with genotype 1a infection with cirrhosis who previously didn’t respond to pegylated interferon and ribavirin (PR).
Common Side Effects Reported in Clinical Trials:
- Can’t sleep (insomnia)